L-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 5, 2013, Pages 783-792

  Bai, Ming ^a   Yang, Zhiping ^a   Qi, Xingshun ^a   Fan, Daiming ^a   Han, Guohong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cirrhosis; Hepatic encephalopathy; l ornithine l aspartate; Meta analysis

Indexed keywords

AMMONIA; LACTULOSE; ORNITHINE ASPARTATE; PLACEBO; PROBIOTIC AGENT;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; AMMONIA BLOOD LEVEL; ARTICLE; DATA BASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FLATULENCE; HEPATIC ENCEPHALOPATHY; HUMAN; INCIDENCE; LIVER CIRRHOSIS; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW;

EID: 84876982943     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12142     Document Type: Article

References (35)

1. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 2002; 35: 716-721.
2. Cordoba J. New assessment of hepatic encephalopathy. J. Hepatol. 2011; 54: 1030-1040.
3. Amodio P, Del Piccolo F, Petteno E etal. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J. Hepatol. 2001; 35: 37-45.
4. Poordad FF. Review article: the burden of hepatic encephalopathy. Aliment. Pharmacol. Ther. 2007; 25 (Suppl. 1): 3-9.
5. Bajaj JS, Saeian K, Schubert CM etal. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009; 50: 1175-1183.
6. Haussinger D, Schliess F. Pathogenetic mechanisms of hepatic encephalopathy. Gut 2008; 57: 1156-1165.
7. Ong JP, Aggarwal A, Krieger D etal. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am. J. Med. 2003; 114: 188-193.
8. Kircheis G, Nilius R, Held C etal. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. Hepatology 1997; 25: 1351-1360.
9. Blei AT, Cordoba J. Hepatic encephalopathy. Am. J. Gastroenterol. 2001; 96: 1968-1976.
10. Morgan MY, Blei A, Grungreiff K etal. The treatment of hepatic encephalopathy. Metab. Brain Dis. 2007; 22: 389-405.
11. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM 2010; 103: 9-16.
12. Als-Nielsen B, Gluud LL, Gluud C. Nonabsorbable disaccharides for hepatic encephalopathy. Cochrane Database Syst. Rev. 2004; (2): CD003044.
13. Als-Nielsen B, Gluud LL, Gluud C. Dopaminergic agonists for hepatic encephalopathy. Cochrane Database Syst. Rev. 2004; (4): CD003047.
14. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst. Rev. 2004; (2): CD002798.
15. Eltawil KM, Laryea M, Peltekian K, Molinari M. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. World J. Gastroenterol. 2012; 18: 767-777.
16. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst. Rev. 2011; (11): CD008716.
17. Stauch S, Kircheis G, Adler G etal. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. J. Hepatol. 1998; 28: 856-864.
18. Ahmad I, Khan AA, Alam A etal. L-ornithine-L-aspartate infusion efficacy in hepatic encephalopathy. J. Coll. Physicians Surg. Pak. 2008; 18: 684-687.
19. Schmid M, Peck-Radosavljevic M, Konig F, Mittermaier C, Gangl A, Ferenci P. A double-blind, randomized, placebo-controlled trial of intravenous L-ornithine-L-aspartate on postural control in patients with cirrhosis. Liver Int. 2010; 30: 574-582.
20. Abid S, Jafri W, Mumtaz K etal. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. J. Coll. Physicians Surg. Pak. 2011; 21: 666-671.
21. Ndraha S, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med. Indones. 2011; 43: 18-22.
22. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 2011; 23: 725-732.
23. Poo JL, Gongora J, Sanchez-Avila F etal. Efficacy of oral L-ornithine-L-aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann. Hepatol. 2006; 5: 281-288.
24. Perez Hernandez JL. Higuera de la Tijera F, Serralde-Zuniga AE, Abdo Francis JM. Critical analysis of studies evaluating the efficacy of infusion of L-ornithine L-aspartate in clinical hepatic encephalopathy in patients with liver failure. Ann. Hepatol. 2011; 10 (Suppl. 2): S66-69.
25. Hu W, Tang S. Efficacy of L-ornithine-L-aspartate in the treatment of hepatic encephalopathy: a systematic review. Chin. J. Evid. Based Med. 2012; 12: 799-803.
26. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration, 2011. Cited July 2012. Available from URL: http://www.cochrane-handbook.org
27. Albillos A, Banares R, Gonzalez M, Catalina MV, Molinero LM. A meta-analysis of transjugular intrahepatic portosystemic shunt versus paracentesis for refractory ascites. J. Hepatol. 2005; 43: 990-996.
28. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stata. In: Egger M, Smith GD, Altman D, eds. Systematic Reviews in Health Care. London: Blackwell: BMJ Books, 2001; 357.
29. Als-Nielsen B, Gluud LL, Gluud C. Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomised trials. BMJ 2004; 328: 1046.
30. Rose C, Michalak A, Rao KV, Quack G, Kircheis G, Butterworth RF. L-ornithine-L-aspartate lowers plasma and cerebrospinal fluid ammonia and prevents brain edema in rats with acute liver failure. Hepatology 1999; 30: 636-640.
31. Rose C, Michalak A, Pannunzio P etal. L-ornithine-L-aspartate in experimental portal-systemic encephalopathy: therapeutic efficacy and mechanism of action. Metab. Brain Dis. 1998; 13: 147-157.
32. Jiang Q, Jiang XH, Zheng MH, Chen YP. L-ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. J. Gastroenterol. Hepatol. 2009; 24: 9-14.
33. Moher D, Pham B, Klassen TP etal. What contributions do languages other than English make on the results of meta-analyses? J. Clin. Epidemiol. 2000; 53: 964-972.
34. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr. Med. Res. Opin. 1993; 13: 109-118.
35. Rees CJ, Oppong K, Al Mardini H, Hudson M, Record CO. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial. Gut 2000; 47: 571-574.